Quoin Pharmaceuticals Ltd ADR (QNRX) Stock Price, Quote & News

Company Profile

Quoin Pharmaceuticals, Ltd., a late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). It also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat Netherton Syndrome; and QRX008 for the treatment of scleroderma. It has a research agreement with Queens...

Industry: Biotechnology

Sector: Healthcare

Phone: 703 980 4182

Website: quoinpharma.com

Address:

42127 Pleasant Forest Court, Ashburn, United States

DexterTrader Jun. 16 at 7:58 PM

Looks like people are starting to shift in to ticker ULY now. Huge insider buying going on! Float is so tiny here only 780k shares. once 5$ breaks this could move into 10-15$ range real fast from there… Something is brewing on ticker ULY - could be this weeks top micro float runner! $ILLR $BTC.X $KITT $QNRX looks good

0 · Reply

StayPresent Jun. 14 at 1:12 AM

$QNRX giant pos scam. This is OTC garbage without the RS.

0 · Reply

WhoDoneIt69 Jun. 13 at 3:26 PM

$QNRX There’s so much room to dilute!!!

0 · Reply

Tofer85 Jun. 11 at 8:50 PM

$JAGX $LYRA $PLRZ $QNRX $TAOP really 🤦‍♂️

0 · Reply

BreakoutBetter Jun. 11 at 6:36 PM

$JAGX low float verging breakout $TAOP $LYRA $PLRZ $QNRX rs

0 · Reply

Stmkr Jun. 11 at 12:25 PM

$AZTR $QNRX Among the next penny stocks overdue for a spike

0 · Reply

ShadowSnake Jun. 9 at 12:51 PM

$RNAZ $QNRX They took $TNXP under $7 after their reverse split and look where they are now!!!

0 · Reply

ShadowSnake Jun. 7 at 10:22 PM

$QNRX I need this to move like $TNXP …

1 · Reply

TwongStocks Jun. 4 at 8:08 PM

$QNRX SEC filing. Bonuses paid out. https://www.sec.gov/ix?doc=/Archives/edgar/data/1671502/000110465925056378/tm2517172d1_8k.htm On May 29, 2025, the Compensation Committee of the Board of Directors of Quoin Pharmaceuticals Ltd. (the “Company”) approved 2024 annual cash bonuses for Dr. Michael Myers and Ms. Denise Carter of $331,238 and $264,640, respectively, consistent with the terms of the CEO Compensation Program and the COO Compensation Program, as applicable, approved at the Company’s 2024 annual meeting of shareholders held on December 5, 2024.

0 · Reply

LimitCess Jun. 4 at 5:53 PM

$ZEO $UPC $QNRX $NCL >> $ALZN 🦍

0 · Reply

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome

May 14, 2025, 7:30 AM EDT - 4 weeks ago

Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study

Apr 30, 2025, 7:30 AM EDT - 6 weeks ago

Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Apr 10, 2025, 7:30 AM EDT - 2 months ago

Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign

Apr 2, 2025, 7:30 AM EDT - 2 months ago

Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient

Mar 31, 2025, 4:18 AM EDT - 2 months ago

Sphere Bio launches Cyto-Cellect Human IgG Kappa and Viability Assay Kit for efficient single-cell selection

Mar 25, 2025, 7:30 AM EDT - 2 months ago

Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases

Mar 13, 2025, 7:30 AM EDT - 3 months ago

Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Mar 4, 2025, 7:30 AM EST - 3 months ago

Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications

Feb 27, 2025, 7:30 AM EST - 3 months ago

Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study

Feb 25, 2025, 7:30 AM EST - 3 months ago

Quoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton Syndrome

Feb 4, 2025, 7:30 AM EST - 4 months ago

Quoin Pharmaceuticals Launches ‘NETHERTON NOW' Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure

Jan 23, 2025, 8:30 AM EST - 5 months ago

Quoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome

Jan 23, 2025, 5:30 AM EST - 5 months ago

Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies

Jan 6, 2025, 8:30 AM EST - 5 months ago

Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study

Dec 20, 2024, 9:20 AM EST - 6 months ago

Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering

Dec 19, 2024, 8:00 AM EST - 6 months ago

Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study

Dec 18, 2024, 8:18 AM EST - 6 months ago

Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies

Oct 31, 2024, 4:05 PM EDT - 8 months ago

Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024

Sep 9, 2024, 8:30 AM EDT - 10 months ago

Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO

Aug 8, 2024, 8:30 AM EDT - 11 months ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results

Aug 6, 2024, 5:00 AM EDT - 11 months ago

Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome

Aug 1, 2024, 4:10 PM EDT - 11 months ago

Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Jun 25, 2024, 4:05 PM EDT - 1 year ago

Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference

Jun 12, 2024, 8:00 AM EDT - 1 year ago

Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland

May 9, 2024, 8:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results

May 2, 2024, 4:10 PM EDT - 1 year ago

Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024

Mar 14, 2024, 12:57 PM EDT - 1 year ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q4 2023 Earnings Call Transcript

Mar 13, 2024, 4:05 PM EDT - 1 year ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results

Mar 7, 2024, 4:05 PM EST - 1 year ago

Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET

Feb 14, 2024, 9:00 AM EST - 1 year ago

Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome

Dec 13, 2023, 8:30 AM EST - 1 year ago

Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome

Nov 9, 2023, 10:51 AM EST - 1 year ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 5:46 PM EST - 1 year ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results

Nov 3, 2023, 8:41 AM EDT - 1 year ago

Quoin Pharmaceuticals Announces Third Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday November 9th at 8:30 am ET

Oct 24, 2023, 9:32 AM EDT - 1 year ago

REPEAT -- Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome

Oct 24, 2023, 8:28 AM EDT - 1 year ago

Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome

Aug 7, 2023, 1:24 AM EDT - 2 years ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q2 2023 Earnings Call Transcript

Aug 2, 2023, 4:45 PM EDT - 2 years ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2023 Financial Results

May 24, 2023, 8:15 AM EDT - 2 years ago

Quoin Pharmaceuticals Announces 50% Enrollment in Open Label Netherton Syndrome Clinical Trial

May 12, 2023, 4:43 PM EDT - 2 years ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q1 2023 Earnings Call Transcript

May 8, 2023, 5:00 PM EDT - 2 years ago

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial Results

May 2, 2023, 8:30 AM EDT - 2 years ago

Quoin Pharmaceuticals Announces First Quarter 2023 Financial Results and Corporate Update Conference Call to Be Held on Tuesday, May 9, 2023 at 8:30 am ET

Mar 21, 2023, 8:30 AM EDT - 2 years ago

Quoin Pharmaceuticals Doses First Patient in Open Label Netherton Syndrome Clinical Trial

Mar 9, 2023, 2:27 PM EST - 2 years ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q4 2022 Earnings Call Transcript

Mar 8, 2023, 5:08 PM EST - 2 years ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and Full Year 2022 Financial Results

Mar 2, 2023, 4:05 PM EST - 2 years ago

Quoin Pharmaceuticals Announces 2022 Corporate Update Conference Call to be held on Thursday March 9th at 8:30am ET

Feb 22, 2023, 8:39 AM EST - 2 years ago

Quoin Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

Dec 13, 2022, 8:30 AM EST - 2 years ago

Quoin Pharmaceuticals Announces Dosing of First Patient in Clinical Trial in Netherton Syndrome

Nov 10, 2022, 2:38 PM EST - 2 years ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q3 2022 Earnings Call Transcript

DexterTrader Jun. 16 at 7:58 PM

0 · Reply

StayPresent Jun. 14 at 1:12 AM

$QNRX giant pos scam. This is OTC garbage without the RS.

0 · Reply

WhoDoneIt69 Jun. 13 at 3:26 PM

$QNRX There’s so much room to dilute!!!

0 · Reply

Tofer85 Jun. 11 at 8:50 PM

$JAGX $LYRA $PLRZ $QNRX $TAOP really 🤦‍♂️

0 · Reply

BreakoutBetter Jun. 11 at 6:36 PM

$JAGX low float verging breakout $TAOP $LYRA $PLRZ $QNRX rs

0 · Reply

Stmkr Jun. 11 at 12:25 PM

$AZTR $QNRX Among the next penny stocks overdue for a spike

0 · Reply

ShadowSnake Jun. 9 at 12:51 PM

$RNAZ $QNRX They took $TNXP under $7 after their reverse split and look where they are now!!!

0 · Reply

ShadowSnake Jun. 7 at 10:22 PM

$QNRX I need this to move like $TNXP …

1 · Reply

TwongStocks Jun. 4 at 8:08 PM

0 · Reply

LimitCess Jun. 4 at 5:53 PM

$ZEO $UPC $QNRX $NCL >> $ALZN 🦍

0 · Reply

Mickey523 Jun. 4 at 3:15 PM

$QNRX $UPC $AUUD $ZCAR all eyes on 👉 $ALZN

0 · Reply

ZacksSCR May. 28 at 5:16 PM

$QNRX: With FDA Clearance to Initiate 2nd NS Whole Body Study for QRX003, Clinical Activities Expand Further https://buff.ly/JQRytst

0 · Reply

PenkeTrading May. 28 at 10:29 AM

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Quoin Pharmaceuticals Ltd DRC. Is that bullish or bearish? $QNRX #Quoin #RsiOverbought #NASDAQ

0 · Reply

bikistocktwit May. 26 at 3:55 PM

$QNRX $RGC squeeeeezee !!! Like $RGC

3 · Reply

9Volt May. 23 at 7:10 PM

$QNRX $QNRX looks great, I only need $358 until I have my purchase price per share back

1 · Reply

Trade4Keeps May. 23 at 5:41 PM

Recent sub 1mil float reverse split stocks $SBET (was sub 1m but recent offering) $RNAZ 800k OS $CDT 800k OS $QNRX 600k OS $DGLY also split, has about 1.6m OS

2 · Reply

StayPresent May. 23 at 12:47 AM

$QNRX 💩

0 · Reply

bikistocktwit May. 22 at 6:52 PM

$QNRX ... nice !!

0 · Reply

prismmarketview May. 22 at 2:49 PM

$QNRX https://prismmarketview.com/quoin-pharmaceuticals-receives-fda-clearance-for-second-pivotal-qrx003-study-in-netherton-syndrome/

0 · Reply

Bornjever May. 22 at 1:59 PM

$BON $HIMS $NVO $QNRX actually the smart ones are China as they know a winner in rare and horrible disease and do not test 5-6 years while folks die and suffer and costs sky rocket on medication. This drug works and the evidence is there.

0 · Reply

ShadowSnake May. 22 at 1:03 PM

$QNRX why am I not surprised …

0 · Reply

callmerubberneck May. 22 at 11:58 AM

$QNRX 140.00? Break even

0 · Reply

Market Cap	4.93M
Revenue (ttm)	0.00
Net Income (ttm)	-8.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	13,563
Avg Vol	239,310
Day's Range	N/A - N/A
Shares Out	588,000.00
Stochastic %K	26%
Beta	1.44
Analysts	Strong Sell
Price Target	$50.00